Given a paragraph, generate a claim that is supported by the given paragraph. 1) The claim must contain information from within the paragraph. 2) A sentence within the paragraph can be used as a claim. 3) The claim should not have contradictions within the paragraph. 4) The claim should be at most one sentence long.

[EX Q]: Authorities have managed to mitigate the spread of the virus and the COVID-19 respiratory disease it causes among Singapore’s citizens by rigorous contact tracing and surveillance, earning praise from the World Health Organization. The Ministry of Health reported just 14 cases among Singaporeans and permanent residents on Saturday. But the disease is spreading rapidly within the large migrant worker community, highlighting what rights groups say is a weak link in containment efforts. Authorities have ramped up testing for the disease in the dormitories. Saturday’s new cases takes the total in the city-state, which is under a partial lockdown, to 5,992. It has reported 11 deaths from the disease.
[EX A]: Singapore reports 942 new COVID-19 cases in record daily jump.

[EX Q]: Top doctors fighting Ebola quickly used the case on Tuesday to press the message that people can recover from the potentially deadly disease if they seek proper care. Ebola is dangerous but it is also curable with correct treatment, said Dr. Jean-Jacques Muyembe, director of Congo’s National Institute for Biomedical Research. “Ebola kills quickly and Ebola heals quickly. That’s the message,” said Muyembe, at a press conference in Goma. “These cases were detected very quickly. The husband was infected, he was at home for 10 days and his wife and son were infected,” said Muyembe. “As soon as the response teams detected these cases, they brought them here to the treatment center. We gave them treatment that is effective and here in a short time both are cured.” Muyembe said two new drugs “are now be used to treat Ebola patients because, according to the studies and the results we obtained in the lab, these are the two drugs that are effective.” Muyembe and other scientists announced this week that preliminary results from two trials in Congo found two drugs — made by Regeneron and the U.S. National Institutes of Health — seem to be saving lives. Researchers said more study is needed to nail down how well those two compounds work. The drugs are antibodies that block Ebola. In the trial, significantly fewer people died among those given the Regeneron drug or the NIH’s, about 30%, compared to those who received another treatment. Esperance Nabintu rejoiced that she and her young son had survived Ebola. “May the Lord be praised, I thank the Lord very much. I and my child were sick with Ebola, but God has just healed us. “My brothers, we must not doubt. Ebola exists, “said Nabintu, whose husband was the second Ebola victim to die in Goma. No other Ebola death has been detected since then. After a public announcement that Nabintu and her son, Ebenezer Fataki, 1, had recovered from Ebola, the response team accompanied the two former patients their home in the Kiziba area, where the medical team educated the residents about proper Ebola treatment. There is less danger that Ebola will spread through Goma, the capital of North Kivu province with more than 2 million inhabitants, because about 200 contacts and suspected cases have been identified and have received proper medication, said Muyembe. He said people arriving in Goma are being monitored at the city’s entry points. “People who come from Beni and Butembo (nearby cities where there are many Ebola cases) must be carefully examined, “said Muyembe. “All of the 200 contacts we are following are doing well. We are waiting until the end of the 21-day surveillance period. We are at day 13, so there are still 8 days to go before we can say that Goma has won against Ebola.” Health officials have also vaccinated tens of thousands of people in Congo and surrounding countries in an attempt to stop the outbreak, but the virus has now continued to spread for more than a year. Response efforts have been repeatedly hampered by attacks on health workers and continuing mistrust among the affected communities; many people in the region don’t believe the virus is real and choose to stay at home when they fall ill, infecting those who care for them. ___ Follow Africa news at https://twitter.com/AP_Africa
[EX A]: 2 Ebola patients in Congo “cured” with drugs, say doctors.

[EX Q]: Given that this is an illegal substance banned by the U.S. Drug Enforcement Agency, cost as a therapeutic would be difficult to ascertain. We liked that the story took pains to explain that approval of this drug faces many hurdles. This is a tough one. While the story tells us what percentage of patients benefited from treatment, it does not, in fact, quantify the extent of those benefits–which is precisely what this category is designed to assess. However, the story does do a good–and thorough–job of describing the benefits in qualitative terms. That said, if the story had only chosen one or two examples of changes in the standardized measures of depression or anxiety, this would have received an enthusiastic “Satisfactory” rating. One strong word of caution though: The story cites one source as saying that psilocybin may one day be used to treat a wide range of mental health issues ranging from drug addiction to obsessive-compulsive disorder. The story offers no evidence to support these claims, which were made by a source associated with an organization that exists specifically to promote research on hallucinogens. Substantial claims require substantial evidence. The story would have been much stronger if it had eliminated the unsubstantiated remarks from the source — particularly since they had no bearing on the subject of the story. The story addresses this issue thoroughly. Well done. The story does a good job of both describing the design of the studies and explaining why the study design is relevant. For example, the story notes: “But both [studies] were considered to be double-blind placebo trials — the gold-standard of medical research in which subjects are left to guess whether they have gotten the active study drug or an inactive lookalike.” This is the sort of thing we like to see. However, we did want to note that in the NYU study, researchers did state in the limitations section that there was “limited blinding” — how did that possibly affect the outcomes? No disease mongering here. However, the story should have been more cautious about claims of benefit for conditions ranging far beyond the scope of the research at hand, which focused on mental health problems among people with advanced cancer. The story clearly states who funded the studies, and what that organization’s long-term goals are. Further, the story clearly identified individuals quoted in the story who have ties to the studies or the funding organization. Lastly, the story incorporates input from an independent expert. However, the story would have been stronger if there had been a skeptical take on the research, which saw in some other coverage, such as this New York Times piece. The story does not address other treatment options for anxiety or depression, such as talk therapy or other pharmaceutical interventions. The story does a good job here. For example, the story notes: “[F]inding drugs like psilocybin effective is by no means the final hurdle to their widespread availability. None are currently in production, and no for-profit pharmaceutical company would likely invest millions of dollars to bring to market a pill intended effectively for one-time use.” Well done. This is a close call. The story does do a good job of placing the work in context in regard to overall research involving hallucinogens. That’s enough to earn it a “Satisfactory” rating. However, the story doesn’t mention any of the work done in the past 10 years on the use of psilocybin specifically to address anxiety in cancer patients, such as this 2007 study, this one from 2011, or this one from 2013. Are the results from the two new studies consistent with these earlier findings? Do they differ in a meaningful way? That would be good to know. The story does not appear to rely on a news release.
[EX A]:

Show your work and conclude with the exact phrasing "Therefore, the final answer is [answer]." where [answer] is just the final number or expression that solves the problem.
user
Ingredient in magic mushrooms is shown to ease anxiety and depression in cancer patients in one dose

